Anzeige
Mehr »
Login
Donnerstag, 25.02.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Adhoc-Meldung: Eine ganz große Überraschung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 852738 ISIN: BE0003739530 Ticker-Symbol: UNC 
Tradegate
25.02.21
11:27 Uhr
87,38 Euro
+5,68
+6,95 %
Branche
Pharma
Aktienmarkt
EURONEXT-100
BEL-20
1-Jahres-Chart
UCB SA Chart 1 Jahr
5-Tage-Chart
UCB SA 5-Tage-Chart
RealtimeGeldBriefZeit
86,4286,5411:45
86,5286,5411:45

Aktuelle News zur UCB Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:04UCB Full Year Report 2020: UCB - sustaining growth, now and into the future246· Revenue increased to € 5.3 billion (+9%, +8% CER[1]) net sales to € 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was € 1.4 billion (+1%, -4% CER) or 27%...
► Artikel lesen
UCB Aktie jetzt für 0€ handeln
MiUCB expands partnership with Microsoft to speed up drug development8
MiUCB taps Microsoft to accelerate drug discovery, clinical trials3
DiUCB builds on relationship with Microsoft with new AI deal; Sanofi partners with German AAV vector biotech10
DiUCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development227BRUSSELS and ATLANTA, Feb. 23, 2021 /PRNewswire/ -- Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases...
► Artikel lesen
05.02.UCB's bimekizumab data in plaque psoriasis published in The Lancet8
15.01.Im heutigen Aktientriple: ROCHE, UCB & der europäische Chemiesektor56
13.01.UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy295- Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable - UCB invested €25 million ($29.3 million) and as...
► Artikel lesen
02.12.20Amgen, Takeda, UCB enrol first patient in Covid-19 global platform study24
01.12.20Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study5
01.12.20Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda12
30.11.20COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs14
20.11.20Briviact: Adapter passt in Einzelfällen nicht in die Flaschenöffnung: UCB Pharma informiert darüber, ...4
19.11.20doc.ai and UCB Biopharma Team Up to Develop Breakthrough Artificial Intelligence Models to Advance Care252New digital health trial will leverage state-of-the-art tech to detect and predict myasthenia gravis symptom patterns and flares doc.ai, an enterprise AI platform accelerating digital transformation...
► Artikel lesen
13.11.20UCB boosts gene therapy offering with a pair of new deals4
12.11.20Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB307New research collaboration and licensing agreement with Lacerta provides UCB access to a novel gene therapy program and proprietary AAV capsids ALACHUA, FL / ACCESSWIRE / November 12, 2020 / Lacerta...
► Artikel lesen
12.11.20UCB inks Handl buyout to boost nascent gene therapy unit3
12.11.20UCB boosts gene therapy footprint with two new deals1
12.11.20UCB is beefing up its gene therapy ops with back-to-back deals to buy a startup and sign up a university spinout for discovery work1
12.11.20UCB acquires gene therapy specialist Handl Therapeutics7
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2